Diagnosis and Treatment > Signs and Symptoms
Search for other papers by Ilse C A Bakker in
Google Scholar
PubMed
Search for other papers by Chris D Schubart in
Google Scholar
PubMed
Search for other papers by Pierre M J Zelissen in
Google Scholar
PubMed
Summary
In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs.
Learning points
-
Prolactinoma coinciding with psychosis can represent a therapeutic challenge.
-
In contrast to many other antipsychotic drugs, aripiprazole is associated with a decrease in prolactin levels.
-
Aripiprazole can be a valuable pharmaceutical tool to treat both prolactinoma and psychosis.
Search for other papers by Ahmed Iqbal in
Google Scholar
PubMed
Search for other papers by Peter Novodvorsky in
Google Scholar
PubMed
Search for other papers by Alexandra Lubina-Solomon in
Google Scholar
PubMed
Search for other papers by Fiona M Kew in
Google Scholar
PubMed
Search for other papers by Jonathan Webster in
Google Scholar
PubMed
Summary
Secondary amenorrhoea and galactorrhoea represent a common endocrine presentation. We report a case of an oestrogen-producing juvenile granulosa cell tumour (JGCT) of the ovary in a 16-year-old post-pubertal woman with hyperprolactinaemia amenorrhoea and galactorrhoea which resolved following surgical resection of the tumour. This patient presented with a 9-month history of secondary amenorrhoea and a 2-month history of galactorrhoea. Elevated serum prolactin at 7081 mIU/l and suppressed gonadotropins (LH <0.1 U/l; FSH <0.1 U/l) were detected. Serum oestradiol was significantly elevated at 7442 pmol/l with undetectable β-human chorionic gonadotropin. MRI showed a bulky pituitary with no visible adenoma. MRI of the abdomen showed a 4.8 cm mass arising from the right ovary with no evidence of metastatic disease. Serum inhibin B was elevated at 2735 ng/l. A right salpingo-oophorectomy was performed, and histology confirmed the diagnosis of a JGCT, stage International Federation of Gynaecology and Obstetrics 1A. Immunohistochemical staining for prolactin was negative. Post-operatively, oestrogen and prolactin levels were normalised, and she subsequently had a successful pregnancy. In summary, we present a case of an oestrogen-secreting JGCT with hyperprolactinaemia manifesting clinically with galactorrhoea and secondary amenorrhoea. We postulate that observed hyperprolactinaemia was caused by oestrogenic stimulation of pituitary lactotroph cells, a biochemical state analogous to pregnancy. To the best of our knowledge, this is the first report of hyperprolactinaemia as a result of excessive oestrogen production in the context of a JGCT.
Learning points
-
Hyperprolactinaemia with bilateral galactorrhoea and secondary amenorrhoea has a wide differential diagnosis and is not always caused by a prolactin secreting pituitary adenoma.
-
Significantly elevated serum oestradiol levels in the range seen in this case, in the absence of pregnancy, are indicative of an oestrogen-secreting tumour.
-
JGCTs are rare hormonally active ovarian neoplasms mostly secreting steroid hormones.
-
Serum inhibin can be used as a granulosa cell-specific tumour marker.
-
JGCTs have an excellent prognosis in the early stages of the disease.
Search for other papers by J Bukowczan in
Google Scholar
PubMed
Search for other papers by K Lois in
Google Scholar
PubMed
Search for other papers by M Mathiopoulou in
Google Scholar
PubMed
Search for other papers by A B Grossman in
Google Scholar
PubMed
Search for other papers by R A James in
Google Scholar
PubMed
Summary
Giant prolactinomas are rare tumours of the pituitary, which typically exceed 40 mm in their largest dimension. Impairment of higher cognitive function has been noted post-operatively after transcranial surgery and as a long-term consequence of the radiotherapy treatment. However, there has been little that is reported on such disturbances in relation to the tumour per se, and to our knowledge, there has been none in terms of responsivity to dopamine agonist therapy and shrinkage in these tumours. We present a case of successful restoration of severely impaired cognitive functions achieved safely after significant adenoma involution with medical treatment alone.
Learning points
-
Giant prolactinomas can be present with profound cognitive defects.
-
Dopamine agonists remain in the mainstay first-line treatment of giant prolactinomas.
-
Mechanisms of the reversible cognitive impairment associated with giant prolactinoma treatment appear to be complex and remain open to further studies.
-
Young patients with giant prolactinomas mandate genetic testing towards familial predisposition.
Search for other papers by Niki Margari in
Google Scholar
PubMed
Search for other papers by Jonathan Pollock in
Google Scholar
PubMed
Search for other papers by Nemanja Stojanovic in
Google Scholar
PubMed
Summary
Prolactinomas constitute the largest subsection of all secretory pituitary adenomas. Most are microprolactinomas and are satisfactorily treated by medical management alone. Giant prolactinomas, measuring more than 4 cm in diameter, are rare and usually occur more commonly in men. Macroprolatinomas tend to present with symptoms of mass effect rather than those of hyperprolactinaemia. Dopamine agonists (DA) are the treatment of choice for all prolactinomas. Surgery is usually reserved for DA resistance or if vision is threatened by the mass effects of the tumour. We describe the case of a 52 year-old woman with a giant invasive prolactinoma who required multiple surgical procedures as well as medical management with DA. One of the surgical interventions required a posterior approach via the trans cranial sub occipital transtentorial approach, a surgical technique that has not been previously described in the medical literature for this indication. The giant prolactinoma was reduced significantly with the above approach and patient symptoms from the compressing effects of the tumour were resolved. This case highlights the importance of a multidisciplinary approach to the management of such patients who present with florid neurological sequelae secondary to pressure effects. Although this presentation is uncommon, surgery via a sub occipital transtentorial approach may be considered the treatment of choice in suitable patients with giant invasive prolactinomas compressing the brainstem.
Learning points
-
Giant prolactinomas present with symptoms of mass effect or those of hyperprolactinaemia.
-
Interpretation of the pituitary profile is crucial to guide further investigations and management.
-
Treatment of giant invasive prolactinomas may involve a combination of medical management and multiple surgical interventions.
-
Treatment with DA may cause pituitary haemorrhage or infarction in patients with these tumours.
-
A sub occipital transtetorial approach may be considered the treatment of choice in invasive prolactinomas compressing the brainstem.
-
Multidisciplinary approach of such patients is fundamental for a better outcome.
Search for other papers by Maryam Rahman in
Google Scholar
PubMed
Search for other papers by Ignacio Jusué-Torres in
Google Scholar
PubMed
Search for other papers by Abdulrahman Alkabbani in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Fausto J Rodríguez in
Google Scholar
PubMed
Search for other papers by Alfredo Quinones-Hinojosa in
Google Scholar
PubMed
Summary
Pituitary adenomas are usually solitary lesions. Rarely, patients may present with two distinct pituitary tumors. We report a case of synchronous secretory pituitary adenomas in a woman who initially presented with elevated prolactin levels. She was initially treated with cabergoline, but, after many years, she began developing symptoms consistent with acromegaly. Imaging revealed two distinct tumors within the pituitary gland. Endocrinological investigation confirmed acromegaly. At the time of surgery, two separate tumors were identified and resected. Pathological analysis demonstrated one tumor as a prolactinoma, and the other tumor as a GH-secreting adenoma. Postoperatively, her GH and IGF1 levels normalized, while the prolactin level remained slightly above normal. This case highlights that GH and prolactin level elevation is not always from co-secretion by the same adenoma.
Learning points
-
Synchronous pituitary adenomas represent <0.5% of pituitary tumors requiring surgery.
-
In the setting of elevated GH and prolactin levels, one cannot assume that they are co-secreted by the same adenoma.
-
A careful study of hormonal workup and pre-operative imaging is necessary for synchronous pituitary adenomas to assure resection of both tumors.
Search for other papers by Siew Hui Foo in
Google Scholar
PubMed
Search for other papers by Shahada A H Sobah in
Google Scholar
PubMed
Summary
Hypopituitarism is a rare presentation of Burkitt's lymphoma (BL). The purpose of this report is to present a case of BL presenting with panhypopituitarism and to review other case reports of lymphoma presenting with pituitary dysfunction to highlight the distinguishing features of these cases from other benign aetiologies of pituitary dysfunction such as non-functioning pituitary adenomas. We reviewed a total of 11 cases of lymphoma presenting with pituitary dysfunction published from 1998 to 2013 including the present case. The demographics, clinical presentations, laboratory features, radiological findings, histological diagnosis, treatment administered and outcomes were described. Of the total number of patients, 45.5% of the cases had diffuse large B-cell lymphoma while 27.3% had BL. Anterior pituitary dysfunction was more common than posterior pituitary dysfunction at presentation. The other common associated presenting symptoms were painful ophthalmoplegia, cranial nerve palsies and constitutional symptoms. Hypothalamic–pituitary abnormalities were often demonstrated radiologically to be associated with cavernous sinus and/or stalk involvement. All patients who completed immunochemotherapy responded haematologically. Pituitary dysfunction also improved in most cases although the recovery tended to be partial. In conclusion, a high index of suspicion of underlying malignancy, such as lymphoma, should be present in patients presenting with acute pituitary dysfunction associated with painful ophthalmoplegia, rapidly evolving neurological features, radiological features atypical of a pituitary adenoma and constitutional symptoms. An early diagnosis is essential as prompt initiation of definitive therapy will induce disease remission and recovery of pituitary dysfunction.
Learning points
-
Hypopituitarism may be the presenting symptom of lymphoma in the absence of associated overt symptoms or signs of a haematological malignancy resulting in delay in diagnosis and institution of treatment.
-
Pituitary dysfunction due to tumour infiltration has a greater tendency to involve the posterior pituitary and infundibulum resulting in diabetes insipidus and hyperprolactinaemia compared with a non-functioning pituitary adenoma.
-
The common associated symptoms of hypopituitarism due to lymphoma infiltration of the hypothalamic–pituitary system include painful ophthalmoplegia, cranial nerve palsies and constitutional symptoms.
-
Radiological abnormalities of the hypothalamic–pituitary region are usually present and often associated with cavernous sinus or stalk involvement.
-
With early institution of definitive treatment, both haematological response and improvement of pituitary dysfunction are expected although the reversal of hypopituitarism tends to be partial and delayed.
-
A high index of suspicion of underlying malignancy such as lymphoma should be present in patients presenting with acute pituitary dysfunction associated with painful ophthalmoplegia, radiological features atypical of pituitary adenomas and constitutional symptoms to enable early diagnosis and prompt initiation of definitive therapy.
Search for other papers by Ramez Ibrahim in
Google Scholar
PubMed
Search for other papers by Atul Kalhan in
Google Scholar
PubMed
Search for other papers by Alistair Lammie in
Google Scholar
PubMed
Search for other papers by Christine Kotonya in
Google Scholar
PubMed
Search for other papers by Ravindra Nannapanenni in
Google Scholar
PubMed
Search for other papers by Aled Rees in
Google Scholar
PubMed
Summary
A 30-year-old female presented with a history of secondary amenorrhoea, acromegalic features and progressive visual deterioration. She had elevated serum IGF1 levels and unsuppressed GH levels after an oral glucose tolerance test. Magnetic resonance imaging revealed a heterogeneously enhancing space-occupying lesion with atypical extensive calcification within the sellar and suprasellar areas. Owing to the extent of calcification, the tumour was a surgical challenge. Postoperatively, there was clinical, radiological and biochemical evidence of residual disease, which required treatment with a somatostatin analogue and radiotherapy. Mutational analysis of the aryl hydrocarbon receptor-interacting protein (AIP) gene was negative. This case confirms the relatively rare occurrence of calcification within a pituitary macroadenoma and its associated management problems. The presentation, biochemical, radiological and pathological findings are discussed in the context of the relevant literature.
Learning points
-
Calcification of pituitary tumours is relatively rare.
-
Recognising calcification in pituitary adenomas on preoperative imaging is important in surgical decision-making.
-
Gross total resection can be difficult to achieve in the presence of extensive calcification and dictates further management and follow-up to achieve disease control.
